Publications

18.11.25

Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study

ConferenceMethodologyMIDDOncologyPharmacometricsSpecial considerations

ACoP15 (Oct 2025), Poster: M-115

Le Louedec F, Kang J, Sarr C, Neldemo I, Wiens M, Baron K, Lamar M, Pérez-Pitarch A, Schmid U, Sailer R, Bergstrand M, Busse D.

28.10.25

The evolving role of in vitro – in vivo correlation in Model-Informed Drug Development: A multi-stakeholder perspective

JournalMIDDPBPK/PBBMPharmacometricsProgram strategies and efficienciesRegulatory interactions

CPT Pharmacometrics Syst Pharmacol. 2025 Oct 28. Online ahead of print.

Chenel M, Fouliard S, Hansson E, Brendel K, Jacobs M, Lennernäs H, Sjögren E, Bergstrand M.

01.10.25

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

JournalMIDDOncologyPharmacometrics

CPT Pharmacometrics Syst Pharmacol. 2025 Oct 1.

Hong Y, Peigné S, Pan Y, Friberg Hietala S, Mc Laughlin AM, Tajima N, Uema D, Zebger-Gong H, Tang Z, Zhou D, Abutarif M, Garimella T.

24.09.25

An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design

JournalMethodologyPBPK/PBBMTrial design and analysis

CPT Pharmacometrics Syst Pharmacol. 2025 Sep 24. Online ahead of print.

Hamadeh A, Pellowe M, Chelle P, Yeung CHT, Otalvaro J, Yamada W, Bartroff J, Kryshchenko A, Dallmann A, Solodenko J, Lippert J, Tsakalozou E, Neely M, Edginton A..

30.07.25

Pharmacometrics education for all by overcoming language barriers to enhance global collaboration

Pharmacometrics

J Pharmacokinet Pharmacodyn. 2025 Jul 30;52(4):46.

Khier S, Chan Kwong AHP, Harnichard M, Ait-Oudhia S.

Below we provide links to posters, white papers and scientific publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 222

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 222

Related content

Science and Services

Case studies

Scientific Publication